AIM
AIM ImmunoTech Inc.
There isn't enough reported data to score AIM yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
AIM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AIM's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
AIM PE Valuation
AIM has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
AIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect AIM's losses to shrink, with revenue declining.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
AIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.79 | +$11.85 |
| Q2 2026 | -$9.10 | +$14.84 |
| Q1 2026 | -$12.24 | +$11.04 |
| Q4 2025 | -$16.40 | +$13.67 |
| Q3 2025 | -$19.64 | +$25.95 |
| Q2 2025 | -$23.94 | +$31.35 |
| Q1 2025 | -$23.28 | +$38.80 |
| Q4 2024 | -$30.07 | +$28.13 |
AIM is still losing money, but far less than before: $7.79 per share over the past year, against $546.07 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over AIM on earnings quality, reporting a profit while its opponent remains loss making.
AIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22K | -15% |
| Q2 2026 | $26K | +4% |
| Q1 2026 | $22K | +38% |
| Q4 2025 | $21K | -53% |
| Q3 2025 | $26K | -26% |
| Q2 2025 | $25K | -50% |
| Q1 2025 | $16K | -60% |
| Q4 2024 | $45K | -31% |
AIM's revenue has slid since its 2023 peak: $22,000 last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13441% | -4029 points |
| Q2 2026 | -13512% | -2928 points |
| Q1 2026 | -10118% | +12501 points |
| Q4 2025 | -14057% | -1046 points |
| Q3 2025 | -9412% | +3414 points |
| Q2 2025 | -10584% | -3196 points |
| Q1 2025 | -22619% | -8284 points |
| Q4 2024 | -13011% | +8534 points |
AIM's operating margin was −13441% last quarter, down 4029 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over AIM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over AIM on profitability, with a higher operating margin.
AIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.6M | -$3.1M |
| Q1 2026 | -$2.7M | -$358K |
| Q2 2025 | -$1.5M | +$1.5M |
| Q1 2025 | -$2.4M | +$2.5M |
| Q2 2024 | -$3M | -$850K |
| Q1 2024 | -$4.8M | -$1.1M |
| Q4 2021 | -$5.8M | -$2.9M |
| Q3 2021 | -$3.5M | -$472K |
AIM has burned cash in almost every quarter: −$12M over the past year, against −$14M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
AIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +90% | +15.4M shares |
| 1 year | +4051% | +31.7M shares |
| 3 years | +6411% | +32M shares |
| 5 years | +8001% | +32.1M shares |
AIM has 32M diluted shares, up 4051% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over AIM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
AIM Net Leverage
AIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
AIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 5.5 | Oversold |
AIM's weekly RSI is 29 (oversold) and its Stochastic is 6 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
AIM PE vs Healthcare Sector
AIM has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 12% below |
| 20 week MA | $0.22 | 32% below |
| 50 week MA | $0.58 | 74% below |
| 100 week MA | $4.33 | 97% below |
| 200 week MA | $22.8 | 99% below |
AIM is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over AIM on trend strength, trading above more of its moving averages.
AIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.8 | $195.0 | +284% |
| 2021 | $195.0 | $103.8 | -47% |
| 2022 | $103.8 | $34.8 | -66% |
| 2023 | $34.8 | $41.4 | +19% |
| 2024 | $41.4 | $19.8 | -52% |
| 2025 | $19.8 | $1.25 | -94% |
| 2026 YTD | $1.25 | $0.15 | -88% |
AIM's yearly returns have swung widely, from +284% in 2020 to −94% in 2025. It's down 88% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over AIM on returns for 2026, with the stronger performance.